Smart insulin pens market seen reaching $160 million by 2030

The Business Research Company says the smart insulin pens market is growing as diabetes cases rise and patients demand more precise insulin delivery. The market is projected to expand from $110 million in 2025 to $160 million by 2030, with North America holding the largest regional share in 2025.

Why it matters: - Smart insulin pens are becoming a bigger part of diabetes care as patients and providers look for more accurate dosing, better tracking and easier routine treatment. - The market’s growth reflects broader pressure from rising diabetes rates and a shift toward connected, data-driven home care. - The category is also tied to wider adoption of digital health tools that can improve adherence and reduce dosing errors.

What happened: - The Business Research Company published its Smart Insulin Pens Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035 on Aug. 27, 2026. - The report says the smart insulin pens market will grow from $0.11 billion in 2025 to $0.12 billion in 2026. - The report forecasts the market will reach $0.16 billion by 2030. - The report says North America held the largest market share in 2025. - Western Europe ranked second in 2025, with Asia-Pacific, South East Asia, Eastern Europe, South America, the Middle East and Africa also included in the analysis.

The details: - Smart insulin pens track dose amount, timing and type while delivering insulin. - The devices can generate reports that healthcare providers can review. - The report links historical growth to rising diabetes prevalence, a larger insulin-dependent population, greater awareness of accurate dosing, growth in home healthcare and wider use of digital health platforms. - The forecast period through 2030 is expected to be supported by deeper integration with digital diabetes ecosystems, broader use of personalized insulin therapies, more remote patient monitoring, stronger demand for data-driven diabetes management and higher investment in smart drug delivery technologies. - The report highlights connected insulin delivery devices, real-time dose tracking, home-based diabetes care and mobile app integration as key trends. - The report also points to patient adherence and safety as major focus areas. - The International Diabetes Federation said there were about 589 million adults ages 20 to 79 living with diabetes globally in 2024. - The International Diabetes Federation expects that figure to rise to 853 million by 2050. - More than 80% of adults with diabetes live in low- and middle-income countries. - The report says the market is expanding because diabetes is more common worldwide and because obesity and physical inactivity are major drivers of Type 2 diabetes. - The report says smart insulin pens help with dosage tracking, reminders and data integration for blood glucose management. - The 2026 report package includes market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based dashboards, market hotspots infographics, and updated graphics and tables. - The company said the new reports also include key technology and future trend analysis. - The report sample is available here. - The full report is available here. - The company also provided contact details for Saumya Sahay and listed social media links, including LinkedIn, LinkedIn company page, Facebook and X.

Between the lines: - The market forecast suggests smart insulin pens are moving from a niche device category toward a more standard part of chronic disease management. - The emphasis on app connectivity and remote monitoring shows the industry is leaning toward systems that connect patients, devices and clinicians rather than standalone hardware. - The strongest near-term opportunity appears to be in home care and digital diabetes ecosystems, where convenience and adherence tools matter most.

What's next: - Market growth is expected to continue through 2030 as connected care, remote monitoring and personalized insulin delivery gain wider adoption. - Further product development is likely to focus on better data integration, safety features and patient adherence tools. - Demand should continue rising as the global diabetes population expands and more care shifts into the home.